A platinum(iv) prodrug to defeat breast cancer through disrupting vasculature and inhibiting metastasis
- 14 February 2019
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 48 (11) , 3571-3575
Abstract
A PtIV prodrug bearing a vascular disrupting agent demonstrates antiangiogenic and antimetastatic potentialities against metastatic triple-negative breast cancer cells.Keywords
Funding Information
- National Natural Science Foundation of China (31570809, 21877059, 21731004)
- Natural Science Foundation of Jiangsu Province (BK20150054)
- National Basic Research Program of China (2015CB856300)
This publication has 31 references indexed in Scilit:
- Hyperthermia-mediated drug delivery induces biological effects at the tumor and molecular levels that improve cisplatin efficacy in triple negative breast cancerJournal of Controlled Release, 2018
- An overview on Vadimezan (DMXAA): The vascular disrupting agentChemical Biology & Drug Design, 2018
- Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in miceActa Pharmacologica Sinica, 2017
- Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasivenessScientific Reports, 2017
- Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast CancerClinical Cancer Research, 2016
- Standard of Care and Promising New Agents for Triple Negative Metastatic Breast CancerCancers, 2014
- Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclinesWorld Journal of Clinical Oncology, 2014
- Triple-negative breast cancer: disease entity or title of convenience?Nature Reviews Clinical Oncology, 2010
- Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast CancerJournal of Clinical Oncology, 2006
- Metastasis: a question of life or deathNature Reviews Cancer, 2006